Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma

48Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Purpose: To evaluate treatment outcome of patients with early-stage favorable Hodgkin's lymphoma (HL) who experience disease relapse after primary treatment with two cycles of chemotherapy followed by radiotherapy (RT). Patients and Methods: Of 1,129 patients with early-stage favorable HL enrolled onto the HD7/HD10/HD13 trials of the German Hodgkin Study Group, 42 patients were identified with treatment failure, of whom eight had primary progressive disease, seven had early relapse (≤ 12 months), and 27 had late relapse (> 12 months). We analyzed this group of patients for risk factors, salvage therapy, and treatment outcome. Results: The median age was 41 years (range, 19 to 72 years); 24 patients were male, 15 patients had outfield relapse, 13 patients infield relapse, and nine patients outfield and infield relapse. At relapse, 24 patients were treated with conventional salvage chemotherapy, 14 patients were treated with high-dose chemotherapy followed by autologous stem-cell transplantation, and four patients were treated with RT alone. At 36 months median follow-up, freedom from second treatment failure (FF2F) and overall survival (OS) were 52% and 67%, respectively. According to the prognostic score for relapsed HL (duration of first remission, clinical stage, and anemia at relapse), patients with two or three poor prognostic features had a significantly worse outcome compared with patients with none or one of these factors (P < .05 for FF2F and OS). Conclusion: Relapse after primary treatment with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine followed by RT is rare. In our analysis, results were influenced by a high treatment-related mortality rate. Additional studies are needed to define the optimal salvage therapy. © 2007 by American Society of Clinical Oncology.

References Powered by Scopus

Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD

1055Citations
N/AReaders
Get full text

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial

1020Citations
N/AReaders
Get full text

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1002Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

165Citations
N/AReaders
Get full text

Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study

160Citations
N/AReaders
Get full text

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): An open-label, randomised, non-inferiority trial

142Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sieniawski, M., Franklin, J., Nogova, L., Glossmann, J. P., Schober, T., Nisters-Backes, H., … Josting, A. (2007). Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. Journal of Clinical Oncology, 25(15), 2000–2005. https://doi.org/10.1200/JCO.2006.10.1386

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

45%

Professor / Associate Prof. 6

30%

Lecturer / Post doc 3

15%

Researcher 2

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 18

78%

Nursing and Health Professions 2

9%

Engineering 2

9%

Social Sciences 1

4%

Save time finding and organizing research with Mendeley

Sign up for free